BALCX | ETNMX | BALCX / ETNMX | |
Total Expense Ratio | 1.31 | 1.02 | 128% |
Annual Report Gross Expense Ratio | 1.31 | 1.09 | 120% |
Fund Existence | 25 years | 10 years | - |
Gain YTD | 13.688 | 6.837 | 200% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 1000 | 25% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 265B | 391M | 67,775% |
Annual Yield % from dividends | 1.12 | 1.83 | 61% |
Returns for 1 year | 7.34 | 3.08 | 238% |
Returns for 3 years | 50.17 | 37.81 | 133% |
Returns for 5 years | 37.49 | 29.06 | 129% |
Returns for 10 years | 67.18 | 86.70 | 77% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JFNNX | 74.04 | 0.29 | +0.39% |
Janus Henderson Global Life Sciences N | |||
HNDDX | 78.73 | N/A | N/A |
Horizon Equity Premium Income Investor | |||
NFEAX | 18.56 | N/A | N/A |
Columbia Large Cap Growth Opp A | |||
MSECX | 11.21 | N/A | N/A |
Morgan Stanley Inst International Eq C | |||
CLBCX | 38.87 | -0.01 | -0.03% |
American Funds American Balanced 529C |